Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730021) titled 'A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors' on July 23.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Astellas Pharma Global Development, Inc.

Condition: Locally Advanced or Metastatic Solid Tumors

Intervention: Drug: ASP388B Drug: Pembrolizumab Drug: Carboplatin Drug: Oxaliplatin

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: August 31, 2026

Target Sample Size: 392

To know mor...